Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus

Drugs

Volumn 70, Issue 17, 2010, Pages 2229-2245

  Mattila, Taina K ^a   De Boer, Anthonius ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Acarbose; Atherosclerosis; Cardiovascular disorders; Chlorpropamide; Coronary artery disease; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; Diet; Exenatide; Glibenclamide; Gliclazide; Glimepiride; Insulins; Metformin; Myocardial infarction; Pioglitazone; Repaglinide; Rosiglitazone; Sitagliptin; Stroke; Sulfonylureas; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; INSULIN; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; GLYCEMIC CONTROL; HEART DEATH; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; STROKE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78449281681     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585220-000000000-00000     Document Type: Review

References (46)

1. WHO. Diabetes Action Now: an initiative of the WorldHealth Organization and the International Diabetes Federation. Geneva: WHO, 2004.
2. Fowler MJ. Microvascular and macrovascular complica-tions of diabetes. Clin Diabetes 2008; 26: 77-82.
3. The A.D.A.M. medical encyclopedia [online]. Availablefrom URL http://www.nlm.nih.gov/medlineplus/encyclo pedia.html [Accessed 2010 Aug 25].
4. Laakso M. Hyperglycaemia and cardiovascular disease intype 2 diabetes. Diabetes 1999; 48: 937-42.
5. Gerstein HC, Pogue J, Mann JFE, et al. The relationshipbetween dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749-55.
6. 1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413-20.
7. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-ana-lysis: glycosylated haemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141:421-31.
8. Stettler C, Alleman S, Juni P, et al. Glycemic control andmacrovascular disease in type 1 and 2 diabetes mellitus: meta-analysis of randomized studies. Am Heart J 2006; 152: 27-38.
9. Fox CS, Coacy S, Sorlie PD, et al. Increasing cardiovasculardisease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115: 1544-50 10.
10. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complicationsin insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
11. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-9.
12. Microalbuminuria Collaborative Study Group. Intensivetherapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbu-minuria. BMJ 1995; 311: 973-7.
13. Lasker RD. The Diabetes Control and Complications Trial:implications for policy and practice. N Engl J Med 1993; 329: 1035-6.
14. The Diabetes Control and Complications Trial ResearchGroup/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342 (6): 381-9.
15. The Diabetes Control and Complications Trial ResearchGroup/ Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
16. Chaturvedi N, Fuller JH. Effect of intensive treatment ininsulin dependent diabetes mellitus with microalbu-minuria: sample size was too small [letter]. BMJ 1996; 312: 253-4.
17. Bender R, Sawicki PT. Effect of intensive treatment in in-sulin dependent diabetes mellitus with microalbuminuria: interpretation of study's results is open to criticism [letter]. BMJ 1996; 312: 254.
18. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulintherapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
19. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
20. UK Prospective Diabetes Study Group. Intensive blood-glucosecontrol with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-65.
21. The Action to Control Cardiovascular Risk in DiabetesStudy Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
22. The ADVANCE Collaborative Group. Intensive bloodglucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
23. Duckworth W, Abraira C, Moritz T, et al. Glucose controland vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 160: 129-39.
24. Nathan DM. Some answers, more controversy, from UKPDS. Lancet 1998; 352: 832-3.
25. UK Prospective Diabetes Study Group. UK ProspectiveDiabetes Study (UKPDS) VIII: study design, progress and performance. Diabetologia 1991; 34: 877-90.
26. Ismail-Beigi F, Craven T, Banerij MA, et al. Effect ofintensive treatment of hyperglycaemia on microvascularoutcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet 2010; 376: 419-30.
27. American Diabetes Association. Standards of medical carein diabetes - 2009. Diabetes Care 2009; 32 Suppl. 1: S13-61.
28. Dluhy RG, McMahon GT. Intensive glycemic control in theACCORD and ADVANCE trials. N Engl J Med 2008; 358: 2630-3.
29. Rosen CJ. Revisiting the rosiglitazone story: lessons learned.N Engl J Med 2010; 363: 803-6.
30. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects ofcardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33 (7): 1578-84.
31. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiolo-gic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33 (5): 983-90.
32. Calles-Escandon J, Lovato LC, Simons-Morton DG, et al.Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33 (4): 721-7.
33. Bonds DE, Miller ME, Bergenstal RM, et al. The associa-tion between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2009; 339: b4909.
34. Miller ME, Bonds DE, Gerstein HC, et al. The effects ofbaseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2009; 339: b5444.
35. Banarer S. Glucose control and vascular complications intype 2 diabetes [letter]. N Engl J Med 2009; 360: 2031.
36. Luan FL. Glucose control and vascular complications intype 2 diabetes. N Engl J Med 2009; 360: 2031-2.
37. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensivecontrol of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373 (9677): 1765-72.
38. Ma J, Yang W, Fang N, et al. The association between in-tensive glycemic control and vascular complications in type 2 diabetes patients. Nutr Metab Cardiovasc Dis 2009; 19 (9): 596-603.
39. Kelly TN, Bazzano LA, Fonseca VA, et al. Systematic re-view: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151 (6): 394-403.
40. Turnbull FM, Abraira C, Anderson RJ, et al. Intensiveglucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-98.
41. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondaryprevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitA-zone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005; 366 (9492): 1279-89.
42. Abraira C, Colwell J, Nuttal F, et al. Cardiovascular eventsand correlates in the veterans affairs diabetes feasibility trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997; 157 (2): 181-8.
43. Gaede P, Vedel P, Larsen N, et al. Multifactorial interven-tion and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348 (5): 383-93.
44. Chaggar PS, Shaw SM, Williams SG. Review article: thia-zolidinediones and heart failure. Diab Vasc Dis Res 2009; 6: 146-52.
45. Akalin S, Berntorp K, Ceriello A, et al. Intensive glucosetherapy and clinical implications of recent data: a consensus statement from the Global Task Force on Gly-caemic Control. Int J Clin Pract 2009; 63 (10): 1421-5.
46. Brown A, Reynolds LR, Bruemmer D. Intensive glycemiccontrol and cardiovascular disease: an update. Nat Rev Cardiol 2010; 7 (7): 369-75